Last Updated2026-06-02

Market View

₹3,169.2(▲1.66%)

Reporting PeriodQ4 FY26

SANOFISanofi India Limited Forensic Risk Analysis

Name: Sanofi India Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassWatch

Market Cap₹8,913 Cr

Primary DriverCompetitive Position

Flagium AI Risk Score

21 / 100

+1 QoQ

Early Deterioration

Sentinel Insight

Financial profile remains stable for now. Weakness is detected in competitive position. This suggests a building risk profile. Risk is increasing at a faster pace.

59.6th %ile (Sector)Accel: +2 Qtrs

Updated2026-06-02

Market View

₹3,169.2▲1.66%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Competitive Position

+15.0 pts

Earnings Quality

+6.0 pts

Final Composite Risk21 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 4 → 21 over 13 quarters.

Expected Direction

⚠ Watch

Primary Deterioration Drivers

Margin Compression
Inventory Stress
Relative Growth Weakness

What to Watch Next Quarter

Operating profit margins
Inventory turnover
Operating cash flow

Active Risk Objects (6)

CriticalHigh

Relative Growth Weakness

📉 Trend DeteriorationAnnualActive for 5 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ4 FY2026

Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Margin Compression

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ3 FY2025

Operating margin declined by 4.8 bps YoY for two consecutive quarters.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Inventory Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ3 FY2024

Inventory growth (62.7%) significantly outpaced revenue growth (2.0%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight6/15

MomentumDecaying

Last SignalFY2024

SANOFI: OCF below Net Profit in 2/3 recent years.

"Cash conversion has normalized in the latest period. Operational cash flow is back in sync."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 4 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ3 FY2026

Working capital expansion detected: Receivable days increased by -5.3%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight10/15

MomentumAccelerating

Last SignalQ4 FY2026

Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	6.42	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+45.0	+47.0	📈 CRITICAL

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹3,169.2(+1.66%)

1M Divergence-9.25%

1 Week-0.89%

1 Month-6.99%

6 Months-26.54%

1 Year-46.85%

2 Year-61.48%

3 Year-51.64%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently consolidating. Recent structural triggers in competitive position suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Continued monitoring is necessary as risk levels remain above institutional safety parameters.

SANOFI • MARKET STRUCTURE

Stage 4 — Declining

The company is in a defensive phase. Sentiment and fundamentals are deteriorating under persistent downward pressure, indicating elevated risk levels.

Stage Transition Prob.0%

Trend QualityDeteriorating

Phase Progression

Phase Progression Score0%

Readiness LabelLow (Early Base Consolidation)

Probability of Advancing0%

CoinTree Momentum

Composite Z-Score-0.8245σ

Weakening momentum trend

Universe Rank#2433 of 2716

Top 89.58% in momentum strength

Timeframe Sparklines

1W-0.9%

1M-7.0%

6M-26.5%

Weinstein Indicators

150 DMA₹3,864.12

200 DMA₹4,105.06

150 DMA Slope-4.5776%Declining

Relative Strength-21.59%Lagging

Relative Turnover (RTR)1.4092

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
SANOFISanofi India Limited	21	60th	+1	6	+2	Competitive PositionWatch
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch
ALBERTDAVDAlbert David Limited	37	90th	-8	27	+0	Balance Sheet StressWatch